Description: Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company's pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Home Page: www.opiant.com
OPNT Technical Analysis
233 Wilshirre Boulevard
Santa Monica,
CA
90401
United States
Phone:
310 598 5410
Officers
| Name | Title |
|---|---|
| Dr. Roger Crystal M.D. | Pres, CEO & Director |
| Mr. David D. O'Toole | Chief Financial Officer |
| Dr. Phillip Skolnick D.Sc. (hon), Ph.D. | Chief Scientific Officer |
| Mr. Ben Atkins | VP of Communications & Investor Relations |
| Mr. Brian Gorman | EVP Corp. Devel. & Gen. Counsel |
| Dr. Mark Heath Ellison Ph.D. | Chief Devel. Officer |
| Mr. Matthew R. Ruth | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 26.738 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.0942 |
| Price-to-Sales TTM: | 4.6801 |
| IPO Date: | 2016-01-04 |
| Fiscal Year End: | July |
| Full Time Employees: | 37 |